The Effect of Doxorubicin on Viability and Morphology of Human Embryonic Stem Cell-derived Cardiomyocytes

Authors

Department of Animal Physiology, College of Science, University of Tehran, Tehran, Iran

Abstract

In spite of serious cardiotoxicity side-effects, doxorubicin is frequently used for treatment of several types of cancers. Isolated human adult cardiomyocytes could be the best model for assessing drug-induced cardiotoxicity, while harvesting mature cardiomyocytes is restricted by some limitations such as biopsy size, cell numbers, viability, proliferative capacity and their disability to be passaged as a cell line. In the present study, human embryonic stem cell (hESC)-derived cardiomyocytes applied as a model for evaluation of doxorubicin cardiotoxicity. In this process, cardiogenic differentiated hESCs spheroids were exposed to different concentrations of doxorubicin for 24, 48 and 72 hours. The viability of spheroids as well as their morphology was assessed as important criterion of cardiotoxicity. Findings of the study showed that the viability of spheroids was significantly reduced at doses of 3 and 30 µM (P<0.05). Moreover, cell morphology was changed in the presence of same doses. Overall hESC-derived cardiomyocytes (hESC-CMs) could be a useful in vitro model for evaluating drug-induced toxicity.

Keywords


  1. Blum R., Carter S., 1974. Adriamycin: A New Anticancer Drug with Significant Clinical Activity. Ann Intern Med. 80: 249ââ‚‌“259.
  2. Xua M.F., Tangb P.L., Qianb Z.M., Ashraf M., 2001. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 68: 889ââ‚‌“901.
  3. Granados S., Quiles J.L., Ramirez-Tortosa C.L., Sanchez-Rovira P., Ramirez-Tortosa M.C., 2010. New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem Toxicol. 48: 1425ââ‚‌“38.
  4. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L., 2004. Anthracyclines : Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol Rev. 56: 185ââ‚‌“229.
  5. Zeevi N., Itskovitz-Eldor J., Binah O., 2012. Cardiomyocytes derived from human pluripotent stem cells for drug screening. Pharmacol Ther. 134: 180ââ‚‌“188.
  6. Denning C., Anderson D., 2008. Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. Drug Discovery Today: Therapeutic Strategies. 5: 223ââ‚‌“232.
  7. Thomson J.A., Waknitz M.A., Swiergiel J.J., Marshall V.S., 1998. Embryonic Stem Cell Lines Derived from Human Blastocysts. Science. 282: 1145ââ‚‌“1147.
  8. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomodo K., Yamanaka S., 2007. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell. 131: 861ââ‚‌“872.
  9. Kehat I., Kenyagin-karsenti D., Snir M., Segev H., Amit M., Gepstein A., Livne E., Binah, O., Itskovitz-eldor J., Gepstein L., 2001. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. 108: 363ââ‚‌“364.
  10. Sartipy P., Bjorquist P., 2011. Concise Review: Human Pluripotent Stem Cell-Based Models for Cardiac and Hepatic Toxicity Assessment. Stem Cell. 29: 744ââ‚‌“748.
  11. Vidarsson H., Hyllner J., Sartipy P., 2010. Differentiation of Human Embryonic Stem Cells to Cardiomyocytes for In Vitro and In Vivo Applications. Stem Cell Reviews and Reports. 6: 108ââ‚‌“120.
  12. Baharvand H., Kazemi Ashtiani S., Taee A., Massumi M., Valojerdi M., Yazdi P., Moradi S., Farrokhi A., 2006. Generation of new human embryonic stem cell lines with diploid and triploid karyotypes. Dev. Growth Differ. 48: 117ââ‚‌“128.
  13. Rezaei Larijani M., Seifinejad A., Pournasr B., Hajihoseini V., Hasani N., Baharvand H., 2011. Long-term Maintenance of Undifferentiated Human Embryonic and Induced Pluripotent Stem Cells in Suspension. Stem Cells Dev. 20: 1911ââ‚‌“1923.
  14. Gonzalez R., Lee J.W., Schultz P.G., 2011. Stepwise Chemically Induced Cardiomyocyte Specification of Human Embryonic Stem Cells. Angew. Chem Int Ed. 2:11181ââ‚‌“11185.
  15. Rajamohan D., Matsa E., Kalra S., Crutchley J., Patel A., George V., à C.D., 2013. Prospects & Overviews Current status of drug screening and disease modelling in human pluripotent stem cells. BioEssays. 35: 281ââ‚‌“298.
  16. Brito-Martins M., Harding S., 2008. beta (1)- and beta (2)-adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non-failing adult human heart. Br J Pharmacol. 153: 751ââ‚‌“759.
  17. Mummery C.L., Zhang J., Ng E.S., Elliott, D.A., Elefanty A.G., Kamp T.J., 2012. Differentiation of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells to Cardiomyocytes A Methods Overview CM. Circulation Res. 111: 344ââ‚‌“358.
  18. Sadek H., Hannack B., Choe E., Wang J., Latif S., Garry M.G., Garry D.J., Longgood J., Frantz D.E., Olson E.N., Hsieh J., Schneider J.W., 2008. Cardiogenic small molecules that enhance myocardial repair by stem cells. Proc Natl Acad Sci USA. 105: 6063- 6068.